Keros Therapeutics, Inc. (KROS)
Stock Price Chart
Key Info
| Market Cap | 911.60M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | n/a |
| Shares Out | 20.17M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Sep 18, 2020 |
| Last Price | $45.19 |
| Previous Close | $44.99 |
| Change ($) | 0.20 |
| Change (%) | 0.44% |
| Day's Open | 45.94 |
| Day's Range | 42.36 - 47.12 |
| Day's Volume | 166,462 |
| 52-Week Range | 19.10 - 65.50 |
More Stats
| Market Cap | 911.60M |
| Enterprise Value | 767.89M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 20.17M |
| Float | 10.47M |
| EPS (basic) | n/a |
| EPS (diluted) | n/a |
| FCF / Share | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.30M |
| Short Ratio | 11.02 |
| Short % of Float | 15.10% |
| Beta | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 182.32 |
| PB Ratio | 6.42 |
| Revenue | 5.00M |
| Operating Income | n/a |
| Net Income | n/a |
| Free Cash Flow | n/a |
| Net Cash | 143.71M |
| Net Cash / Share | 7.12 |
| Gross Margin | -147.58% |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | -34.41% |
| ROE | -186.16% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 |
|---|---|---|
| Revenue | 10.00 | 10.00 |
| Revenue Growth | 0% | - |
| Gross Profit | 10.00 | 10.00 |
| Operating Income | -10.56 | -1.69 |
| Net Income | -14.14 | -2.35 |
| Shares Outstanding | 2.33 | 2.17 |
| Earnings Per Share | -6.08 | -1.08 |
| Operating Cash Flow | -16.00 | 7.04 |
| Capital Expenditures | -0.27 | -0.22 |
| Free Cash Flow | -16.27 | 6.83 |
| Cash & Equivalents | 7.14 | 23.39 |
| Total Debt | 1.28 | 0.79 |
| Net Cash / Debt | 5.86 | 22.60 |
| Assets | 10.96 | 27.41 |
| Liabilities | 10.46 | 14.65 |
| Book Value | -19.45 | -7.18 |
Company Profile
Company Details
| Full Name | Keros Therapeutics, Inc. |
| Country | United States |
| Employees | 28 |
| CEO | Jasbir S. Seehra |
Stock Information
| Ticker Symbol | KROS |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: KROS |
| IPO Date | April 8, 2020 |
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. Address: 99 Hayden Avenue, Lexington, MA, United States, 02421